- Conditions
- Coronavirus, Covid19
- Interventions
- bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,044 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 207
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 3,857
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypercholesterolemia
- Interventions
- Praluent (Alirocumab), Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 2,176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 73
- States / cities
- Auburn, Alabama • Birmingham, Alabama • Mobile, Alabama + 63 more
- Conditions
- Lung Biopsy
- Interventions
- ABPI, BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug
- Other · Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 2
- States / cities
- Harrison, New York • New York, New York
- Conditions
- HIV
- Interventions
- Teduglutide, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Femur Neck Fracture
- Interventions
- Teriparatide, Placebo, Calcium supplementation, Vitamin D supplementation
- Drug · Dietary Supplement
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 21 more
- Conditions
- Asthma
- Interventions
- Lebrikizumab, Montelukast, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 30 more
- Conditions
- Hypoparathyroidism
- Interventions
- rhPTH(1-84)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Friedreich Ataxia
- Interventions
- CTI-1601
- Drug
- Lead sponsor
- Larimar Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years to 60 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Gainesville, Florida + 8 more
- Conditions
- Nasolabial Fold, Cheek Augmentation
- Interventions
- SMI-01
- Device
- Lead sponsor
- Sofregen Medical, Inc.
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Encinitas, California • Miami, Florida
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
- Interventions
- Efimosfermin, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 28
- States / cities
- Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 22 more
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Rebif®, Copaxone®
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 764 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
- Conditions
- Type 1 Diabetes
- Interventions
- Muscle Biopsy, Jell-O with Amino acids, Dextrose
- Procedure · Other · Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Atrophy, Geographic
- Interventions
- GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Otilimab (GSK3196165), csDMARD(s)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,916 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 79
- States / cities
- Anniston, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 63 more
- Conditions
- Myelodysplastic Syndromes (MDS)
- Interventions
- Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
- Combination Product
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 9 more
- Conditions
- Osteoarthritis
- Interventions
- Tanezumab
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- La Mesa, California
- Conditions
- Asthma, Allergic Rhinitis, Atopic Dermatitis
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Crohn's Disease
- Interventions
- Certolizumab Pegol (CDP870)
- Biological
- Lead sponsor
- UCB Pharma SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Lebrikizumab, Pirfenidone, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
- Conditions
- X-Linked Hypophosphatemia
- Interventions
- KRN23
- Biological
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 5
- States / cities
- San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
- Conditions
- Alzheimer Disease, Dementia of Alzheimer Type
- Interventions
- ATH-1017, Placebo
- Drug
- Lead sponsor
- LeonaBio
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 7
- States / cities
- Santa Ana, California • West Palm Beach, Florida • Decatur, Georgia + 4 more
- Conditions
- Psoriasis
- Interventions
- AbGn168 intravenous infusion, AbGn168 subcutaneous injection
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 6
- States / cities
- Boise, Idaho • Evansville, Indiana • Baltimore, Maryland + 3 more
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
- Interventions
- 5-Azacytidine, Ara-C, Valproic Acid (VPA)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bardet-Biedl Syndrome, POMC Deficiency
- Interventions
- Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg, Setmelanotide 20 mg, Setmelanotide 25 mg, Setmelanotide 30 mg
- Drug
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Marshfield, Wisconsin